Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching

Table 1 Baseline characteristics of patients who received triple therapy with pegylated interferon, ribavirin, and telaprevir or simeprevir

	Unmatched patients			Standardized	Propensity score matched patients			Standardized
	Telaprevir	Simeprevir	P value	difference	Telaprevir	Simeprevir	P value	difference
No. of patients	n = 159	n = 147			n = 104	n = 104
Age (yr)	60 (51.0-65.0)	63 (54.5-70.0)	0.002	0.348	61.5 (53.0-65.8)	60.5 (52.0-67.0)	NS	0.0154
Gender (male/female)	77/82	67/80	NS	0.057	45/59	49/55	NS	0.0773
Body mass index (kg/m2)	23.9 (21.7-25.7)	23.2 (21.1-25.0)	NS	0.202	23.6 (21.1-25.3)	23.4 (21.2-25.2)	NS	0.0747
Laboratory data
Level of viremia (log IU/mL)	6.7 (6.3-7.0)	6.8 (6.3-7.2)	NS	0.210	6.7 (6.3-7.0)	6.6 (6.2-7.1)	NS	0.0158
Leukocyte count (/mm3)	5060 (4200-5800)	4920 (4100-5800)	NS	0.094	5000 (4200-5700)	5020 (4150-5800)	NS	0.0272
Hemoglobin (g/dL)	14.1 (13.1-15.0)	13.8 (12.9-14.7)	NS	0.175	14 (13.0-14.8)	13.9 (12.9-15.0)	NS	0.0264
Platelet count (× 104/mm3)	15 (12.5-19.8)	15.1 (11.7-20.1)	NS	0.053	15 (12.9-20.0)	15.1 (11.8-20.1)	NS	0.0032
SNP of IL28B (TT/non-TT/unknown)	99/34/26	89/43/15	NS	0.155	74/30	73/31	NS	0.0211
Other data
Prior treatment response relapse/other	43/30	31/32	NS	0.196	31/22	23/20	NS	0.100

“Unmatched patients” refer to values prior to propensity score matching and “Propensity score matched patients” refer to values after adjustment by propensity score matching. Data are presented as numbers or medians with interquartile ranges in parentheses. P-values were calculated using the χ² or Mann-Whitney U-test for continuous variables. SNP: Single-nucleotide polymorphism; IL28: Interleukin 28B; NS: Not significant.